Author | Suellen Curkendall, PhD

Suellen Curkendall, PhD, is a member of The Degge Group, which specializes in risk management.

Articles

The New Era of Risk Management

Pharmaceutical Executive

Article

FDA has issued the industry a new charge-pay closer attention to risk management. Now that prescription drug user fees have helped the agency approve candidates more rapidly, FDA has returned to its basic mandate: assuring that marketed pharmaceuticals are safe. In the past, that meant clear labeling with adequate directions and warnings based on clinical trials. The agency now believes that product safety extends beyond warning labels and wants to ensure that prescriptions are used safely as well. As a result, it is asking the pharma industry to demonstrate products' safety before approval and to further control their use after